0111 GMT - Sigma Healthcare gets a new bull at UBS on the prospect of multiyear double-digit EPS growth. Initiating coverage of the stock with a buy rating, analyst Shaun Cousins tells clients that the pharmaceutical supplier's reverse takeover by the Chemist Warehouse retail group has created a capital-light business that justifies its elevated consensus multiple of 46.4X fiscal 2026 earnings. He writes in a note that operating leverage, sourcing and synergies will expand Sigma's underlying EBIT margin from fiscal 2025's pro forma 9.4% to 11.6% by fiscal 2030. UBS places a A$3.40 target price on the stock, which is up 1.0% at A$2.95. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
November 19, 2025 20:11 ET (01:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.